JY
ELTX icon

Jeff Yass’s Elicio Therapeutics ELTX Stock Holding History

Jeff Yass’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-70,804
Closed -$711K – 13652
2026
Q1 		$757K Buy
70,804
+6,752
+11% +$65.2K ﹤0.01% 8615
2025
Q4 		$510K Sell
64,052
-56,155
-47% -$510K ﹤0.01% 8741
2025
Q3 		$1.32M Buy
120,207
+103,184
+606% +$1.04M ﹤0.01% 6681
2025
Q2 		$131K Sell
17,023
-14,338
-46% -$89.2K ﹤0.01% 11603
2025
Q1 		$193K Buy
+31,361
New +$243K ﹤0.01% 10967
2022
Q4 		– Sell
-1,366
Closed -$13K – 12713
2022
Q3 		$13K Sell
1,366
-568
-29% -$5.93K ﹤0.01% 12731
2022
Q2 		$22K Buy
+1,934
New +$30.9K ﹤0.01% 12339

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Jeff Yass's ELTX Position: Q2 2026 in Review

Jeff Yass sold out of Elicio Therapeutics (ELTX) in Q2 2026, closing a stake of 70,804 shares — an estimated $711K sold.

Jeff Yass first reported a position in ELTX in Q2 2022 and held it in 7 quarters. The position peaked at $1.32M in Q3 2025. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Jeff Yass reported no remaining Elicio Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 70,804 Elicio Therapeutics shares in Q2 2026, an estimated $711K.
  • Jeff Yass first reported a position in Elicio Therapeutics in Q2 2022 and held it in 7 quarters.
  • Jeff Yass's Elicio Therapeutics position peaked at $1.32M in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.